Summarized by Masters of Longevity from Longevity Docs News.
Tiny Health’s fundraising and shift into adult longevity care makes for a news piece about microbiome testing’s growing role in clinics; it previews what readers can expect about its clinical ambitions and research-focused offerings.
Key Takeaways
- Tiny Health raised $33 million in a Series B round led by B Capital, bringing total funding to $46 million.
- The company is expanding adult offerings and partnered with Mayo Clinic Executive Health and Longevity Programs for a microbiome study in adults 60 and older.
- Strongest published evidence cited is a 2025 randomized pediatric trial showing targeted microbiome intervention cut infant eczema odds by 83%.
